Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Intangibles (2017 - 2025)

Ptc Therapeutics (PTCT) has 9 years of Intangibles data on record, last reported at $396.5 million in Q3 2025.

  • For Q3 2025, Intangibles changed N/A year-over-year to $396.5 million; the TTM value through Sep 2025 reached $396.5 million, changed N/A, while the annual FY2024 figure was $118.8 million, 68.7% down from the prior year.
  • Intangibles reached $396.5 million in Q3 2025 per PTCT's latest filing, up from $118.4 million in the prior quarter.
  • Across five years, Intangibles topped out at $763.7 million in Q1 2022 and bottomed at $118.4 million in Q1 2025.
  • Average Intangibles over 5 years is $507.9 million, with a median of $453.6 million recorded in 2021.
  • Peak YoY movement for Intangibles: soared 55.62% in 2022, then plummeted 68.7% in 2024.
  • A 5-year view of Intangibles shows it stood at $453.6 million in 2021, then surged by 55.62% to $705.9 million in 2022, then tumbled by 46.24% to $379.5 million in 2023, then tumbled by 68.7% to $118.8 million in 2024, then surged by 233.74% to $396.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $396.5 million in Q3 2025, $118.4 million in Q1 2025, and $118.8 million in Q4 2024.